TABLE 3.
Six out of the top 15 pathways emerging from metabolite set enrichment analysis are significant
| Metabolite seta | Total | Hits | Expected | P valueb |
|---|---|---|---|---|
| Pyrimidine metabolism | 39 | 7 | 1.05 | 0.0000494 |
| Nicotinate and nicotinamide metabolism | 15 | 4 | 0.404 | 0.0005 |
| Glycolysis/gluconeogenesis | 26 | 4 | 0.7 | 0.00441 |
| Purine metabolism | 65 | 6 | 1.75 | 0.00666 |
| Pantothenate and CoA biosynthesis | 19 | 3 | 0.512 | 0.013 |
| Biotin metabolism | 10 | 2 | 0.269 | 0.0278 |
| Neomycin, kanamycin, and gentamicin biosynthesis | 2 | 1 | 0.0539 | 0.0532 |
| Butanoate metabolism | 15 | 2 | 0.404 | 0.0596 |
| Tryptophan metabolism | 41 | 3 | 1.1 | 0.0954 |
| Citrate cycle (TCA cycle) | 20 | 2 | 0.539 | 0.0991 |
| Fructose and mannose metabolism | 20 | 2 | 0.539 | 0.0991 |
| β-Alanine metabolism | 21 | 2 | 0.566 | 0.108 |
| Pentose phosphate pathway | 22 | 2 | 0.593 | 0.117 |
| Alanine, aspartate, and glutamate metabolism | 28 | 2 | 0.754 | 0.173 |
| Inositol phosphate metabolism | 30 | 2 | 0.808 | 0.192 |
The data correspond to Fig. 8B; bold font indicates significant pathways.
The top 15 metabolite sets were ranked based on P value. Metabolic sets with a P value of <0.05 were considered significantly altered.